Regulatory T cells in autoimmune endocrine diseases

Trends in Endocrinology and Metabolism

Volumn 19, Issue 8, 2008, Pages 292-299

  Wong, F Susan ^a   Dayan, Colin M ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; CYTOKINE; LYMPHOCYTE SURFACE MARKER;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; BIOLOGY; CELL FUNCTION; CELL ISOLATION; ENDOCRINE DISEASE; EXPERIMENTAL MODEL; GENETIC ANALYSIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW;

ANIMALS; AUTOIMMUNE DISEASES; DISEASE MODELS, ANIMAL; ENDOCRINE SYSTEM DISEASES; HORMONES; HUMANS; MODELS, BIOLOGICAL; T-LYMPHOCYTES, REGULATORY;

EID: 52049094133     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2008.07.007     Document Type: Review

References (80)

1. DeVoss J.J., and Anderson M.S. Lessons on immune tolerance from the monogenic disease APS1. Curr. Opin. Genet. Dev. 17 (2007) 193-200
2. Lohr J., et al. T-cell tolerance and autoimmunity to systemic and tissue-restricted self-antigens. Immunol. Rev. 204 (2005) 116-127
3. Fontenot J.D., et al. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4 (2003) 330-336
4. Yamaguchi T., et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 27 (2007) 145-159
5. Hill J.A., et al. Foxp3 transcription-factor-dependent and -independent regulation of the regulatory T cell transcriptional signature. Immunity 27 (2007) 786-800
6. Zheng Y., et al. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 445 (2007) 936-940
7. Gavin M.A., et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445 (2007) 771-775
8. Sundstedt A., et al. Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J. Immunol. 170 (2003) 1240-1248
9. Battaglia M., et al. Rapamycin and interleukin-10 treatment induces T regulatory type 1 cells that mediate antigen-specific transplantation tolerance. Diabetes 55 (2006) 40-49
10. Najafian N., et al. Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J. Clin. Invest. 112 (2003) 1037-1048
11. Bisikirska B., et al. TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J. Clin. Invest. 115 (2005) 2904-2913
12. Pop S.M., et al. Single cell analysis shows decreasing FoxP3 and TGFbeta1 coexpressing CD4+CD25+ regulatory T cells during autoimmune diabetes. J. Exp. Med. 201 (2005) 1333-1346
13. Tritt M., et al. Functional waning of naturally occurring CD4+ regulatory T-cells contributes to the onset of autoimmune diabetes. Diabetes 57 (2008) 113-123
14. Lundsgaard D., et al. In vivo control of diabetogenic T-cells by regulatory CD4+CD25+ T-cells expressing Foxp3. Diabetes 54 (2005) 1040-1047
15. Poussier P., et al. Impaired post-thymic development of regulatory CD4+25+ T cells contributes to diabetes pathogenesis in BB rats. J. Immunol. 174 (2005) 4081-4089
16. Zipris D., et al. Infections that induce autoimmune diabetes in BBDR rats modulate CD4+CD25+ T cell populations. J. Immunol. 170 (2003) 3592-3602
17. Saitoh O., and Nagayama Y. Regulation of Graves' hyperthyroidism with naturally occurring CD4+CD25+ regulatory T cells in a mouse model. Endocrinology 147 (2006) 2417-2422
18. Nagayama Y., et al. CD4+CD25+ naturally occurring regulatory T cells and not lymphopenia play a role in the pathogenesis of iodide-induced autoimmune thyroiditis in NOD-H2h4 mice. J. Autoimmun. 29 (2007) 195-202
19. Flynn J.C., et al. Depletion of CD4+CD25+ regulatory T cells exacerbates sodium iodide-induced experimental autoimmune thyroiditis in human leucocyte antigen DR3 (DRB1*0301) transgenic class II-knock-out non-obese diabetic mice. Clin. Exp. Immunol. 147 (2007) 547-554
20. Shoda L.K., et al. A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23 (2005) 115-126
21. Guimaraes V.C., et al. Immunosuppression of thyroiditis. Endocrinology 137 (1996) 2199-2207
22. Elias D., and Cohen I.R. Peptide therapy for diabetes in NOD mice. Lancet 343 (1994) 704-706
23. Tisch R., et al. Antigen-specific mediated suppression of beta cell autoimmunity by plasmid DNA vaccination. J. Immunol. 166 (2001) 2122-2132
24. Pop S.M., et al. The type and frequency of immunoregulatory CD4+ T-cells govern the efficacy of antigen-specific immunotherapy in nonobese diabetic mice. Diabetes 56 (2007) 1395-1402
25. Tang Q., et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199 (2004) 1455-1465
26. Tarbell K.V., et al. Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J. Exp. Med. 204 (2007) 191-201
27. Battaglia M., et al. Induction of Tolerance in Type 1 Diabetes via Both CD4+CD25+ T Regulatory Cells and T Regulatory Type 1 Cells. Diabetes 55 (2006) 1571-1580
28. Marie J.C., et al. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J. Exp. Med. 201 (2005) 1061-1067
29. Belghith M., et al. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9 (2003) 1202-1208
30. Bresson D., et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest. 116 (2006) 1371-1381
31. Hu C.Y., et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117 (2007) 3857-3867
32. Wildin R.S., et al. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J. Med. Genet. 39 (2002) 537-545
33. Zavattari P., et al. No association between variation of the FOXP3 gene and common type 1 diabetes in the Sardinian population. Diabetes 53 (2004) 1911-1914
34. Vella A., et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am. J. Hum. Genet. 76 (2005) 773-779
35. Todd J.A., et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat. Genet. 39 (2007) 857-864
36. Jubault V., et al. Sequential occurrence of thyroid autoantibodies and Graves' disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J. Clin. Endocrinol. Metab. 85 (2000) 4254-4257
37. Coles A.J., et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354 (1999) 1691-1695
38. Kukreja A., et al. Multiple immuno-regulatory defects in type-1 diabetes. J. Clin. Invest. 109 (2002) 131-140
39. Brusko T.M., et al. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 54 (2005) 1407-1414
40. Lindley S., et al. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54 (2005) 92-99
41. Tree T.I., et al. A mini meta-analysis of studies on CD4+CD25+ T cells in human type 1 diabetes: report of the Immunology of Diabetes Society T Cell Workshop. Ann. N. Y. Acad. Sci. 1079 (2006) 9-18
42. Jonson C.O., et al. The association of CTLA-4 and HLA class II autoimmune risk genotype with regulatory T cell marker expression in 5-year-old children. Clin. Exp. Immunol. 145 (2006) 48-55
43. Vukmanovic-Stejic M., et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J. Clin. Invest. 116 (2006) 2423-2433
44. Marazuela M., et al. Regulatory T cells in human autoimmune thyroid disease. J. Clin. Endocrinol. Metab. 91 (2006) 3639-3646
45. Preda I., et al. Soluble, dimeric HLA DR4-peptide chimeras: an approach for detection and immunoregulation of human type-1 diabetes. Eur. J. Immunol. 35 (2005) 2762-2775
46. Arif S., et al. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113 (2004) 451-463
47. Herold K.C., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N. Engl. J. Med. 346 (2002) 1692-1698
48. Keymeulen B., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N. Engl. J. Med. 352 (2005) 2598-2608
49. Alleva D.G., et al. Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand. J. Immunol. 63 (2006) 59-69
50. Raz I., et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 358 (2001) 1749-1753
51. Diabetes Prevention Trial - Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N. Engl. J. Med. 346 (2002) 1685-1691
52. Agardh C.D., et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J. Diabetes Complications 19 (2005) 238-246
53. Harrison L.C., et al. Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes. Diabetes Care 27 (2004) 2348-2355
54. Herold K.C., et al. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala). J. Clin. Invest. 111 (2003) 409-418
55. Somerset D.A., et al. Normal human pregnancy is associated with an elevation in the immune suppressive CD25+ CD4+ regulatory T-cell subset. Immunology 112 (2004) 38-43
56. Aluvihare V.R., et al. Regulatory T cells mediate maternal tolerance to the fetus. Nat. Immunol. 5 (2004) 266-271
57. Polanczyk M.J., et al. Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J. Immunol. 173 (2004) 2227-2230
58. Tai P., et al. Induction of regulatory T cells by physiological level estrogen. J. Cell. Physiol. 214 (2008) 456-464
59. Whitacre C.C., et al. A gender gap in autoimmunity. Science 283 (1999) 1277-1278
60. Friedman J.M., and Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 395 (1998) 763-770
61. Matarese G., et al. Leptin in autoimmunity: many questions, some answers. Tissue Antigens 70 (2007) 87-95
62. De Rosa V., et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 26 (2007) 241-255
63. Hori S., et al. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (2003) 1057-1061
64. Fontenot J.D., et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6 (2005) 1142-1151
65. Shevach E.M., and Stephens G.L. The GITR-GITRL interaction: co-stimulation or contrasuppression of regulatory activity? Nat. Rev. Immunol. 6 (2006) 613-618
66. Huang C.T., et al. Role of LAG-3 in regulatory T cells. Immunity 21 (2004) 503-513
67. Sarris M., et al. Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition. Immunity 28 (2008) 402-413
68. Szanya V., et al. The subpopulation of CD4+CD25+ splenocytes that delays adoptive transfer of diabetes expresses L-selectin and high levels of CCR7. J. Immunol. 169 (2002) 2461-2465
69. Sansom D.M., and Walker L.S. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol. Rev. 212 (2006) 131-148
70. Lehmann J., et al. Expression of the integrin alpha Ebeta 7 identifies unique subsets of CD25+ as well as CD25- regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13031-13036
71. Liu W., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 203 (2006) 1701-1711
72. Iellem A., et al. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J. Exp. Med. 194 (2001) 847-853
73. Deaglio S., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med. 204 (2007) 1257-1265
74. Williams L.M., and Rudensky A.Y. Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat. Immunol. 8 (2007) 277-284
75. Taylor A., et al. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 117 (2006) 433-442
76. Li M.O., et al. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 24 (2006) 99-146
77. Kretschmer K., et al. Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 6 (2005) 1219-1227
78. Maynard C.L., et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nat. Immunol. 8 (2007) 931-941
79. Roncarolo M.G., et al. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212 (2006) 28-50
80. Faria A.M., and Weiner H.L. Oral tolerance. Immunol. Rev. 206 (2005) 232-259